Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CG1940 + CG8711
- Development stage
- Discontinued
- Lead developer
- ANI Pharmaceuticals
- Modality
- Adoptive Cell Transfer → Cell Therapies
- Administration
- Intradermal
01
Overview
**CG1940 + CG8711** is a combination immunotherapeutic composed of two allogeneic prostate cancer cell lines, **PC-3 (CG1940)** and **LNCaP (CG8711)**, each genetically modified to secrete granulocyte-macrophage colony-stimulating factor (**GM-CSF**). This cellular vaccine (marketed as **GVAX** for prostate cancer) is designed to present multiple prostate cancer antigens to the patient’s immune system, with GM-CSF acting to enhance antigen presentation by recruiting and activating dendritic cells. This facilitates a multi-antigen T cell-mediated anti-tumor immune response. Developed primarily for use in patients with advanced prostate cancer, especially in settings where immunotherapeutic strategies are investigated as alternatives or adjuncts to chemotherapeutic regimens. Development included both phase II and phase III trials, though phase III was terminated for futility after interim analysis showed insufficient improvement in survival compared to chemotherapy[2][4][5][7].
- Brand names
- GVAX
- Other names
- GVAX prostate cancer vaccine
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)
Beyond the preview
Go deeper on CG1940 + CG8711.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CG1940 + CG8711.